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Received May 12, 2010; accepted April 23, 2011AbstractBackground: The treatment policy and disease process of mucosa-associated lymphoid tissue (MALT) lymphomas are different from those of
other gastrointestinal lymphomas. Chemotherapy has replaced curative surgery as the treatment of choice in gastric lymphomas but the optimal
frontline treatment of intestinal lymphomas has yet to be defined. Hence, we attempted to identify the difference in features between gastric and
intestinal nonMALT lymphomas.
Methods: Patients who were newly diagnosed with nonMALT lymphomas of gastrointestinal origin in our hospital between January 2001 and
February 2010 were included in our study. Patient characteristics and outcomes were retrospectively analyzed.
Results: Among 59 gastric lymphoma patients and 25 intestinal lymphoma patients, the intestinal group were significantly younger and had
better performance ( p¼ 0.002 and 0.042). Whereas gastrointestinal obstruction and intussusception were more common in the intestinal group
( p¼ 0.024 and 0.024), more bleeding episodes were displayed in the gastric counterpart ( p¼ 0.042). Histologically, diffuse large B-cell
lymphoma was more prevalent in the stomach, and enteropathy associated T-cell lymphoma was found only in the intestine ( p¼ 0.006 and
0.024). Despite more intestinal lymphoma patients receiving surgery ( p¼ 0.002), the response rate, overall survival and progression-free
survival were similar to the gastric counterpart ( p¼ 0.1060, 0.7758 and 0.1248). In the multivariate analysis of overall survival, chemo-
therapy (hazard ratio [HR] 0.2; 95% confidence interval [CI] 0.091e0.440; p< 0.001) and International Prognostic Index (HR 1.7; 95% CI
1.181e2.448; p¼ 0.004) proved prognostic in gastric lymphomas. Furthermore, T-cell lineage (HR 8.615; 95% CI 2.165e34.288; p¼ 0.002)
and poor performance (HR 9.374; 95% CI 1.497e58.712; p¼ 0.017) were poor predictors in the intestinal counterpart.
Conclusion: Intestinal lymphomas differ from gastric lymphomas in manifestation, histology, management and prognosis. Surgery still plays
a role in intestinal lymphomas because presentations of surgical emergencies are more common. In addition, the outcome of gastric lymphomas
compared with intestinal lymphomas is no longer superior if patients with MALT lymphomas are excluded. Because of the limited number of
enrolled patients, further large-scale studies are warranted to validate these results.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Gastrointestinal lymphomas account for 10e15% of all non-
Hodgkin’s lymphomas and 30e40% of extranodal lymphomas1* Corresponding author. Dr. Ling-Ping Chen, Division of Hematology and
Oncology, Department of Internal Medicine, Kaohsiung Veterans General
Hospital, 386, Ta-Chung lst Road, Kaohsiung 813, Taiwan, ROC.
E-mail address: xguaalu@yahoo.com.tw (L.-P. Chen).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.08.004but the incidence is increasing.2 The most common site
of gastrointestinal lymphoma involvement is the stomach
(60e75%) followed by the small intestine, ileum, cecum, colon
and rectum.3 The major histological subtypes are diffuse large
B-cell lymphoma (DLBCL) and mucosa-associated lymphoid
tissue (MALT) lymphoma. Helicobacter pylori eradication is
the treatment of choice in MALT lymphoma, which usually has
superior outcomes compared with other subtypes.4,5 Except
for MALT lymphoma, immunochemotherapy with or withouthinese Medical Association. All rights reserved.
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the frontline treatment in gastric lymphomas. An operation is
reserved simply for surgical complications or localized residual
disease after first-line conservative treatment.6,7 By contrast, the
most appropriate treatment modality for intestinal lymphoma is
still controversial.8,9 Patients with MALT lymphoma were
excluded from the study because of the individual treatment
policy and natural course of MALT lymphomas. The clinical
manifestations, managements and survival outcomes between
gastric and intestinal nonMALT lymphomas were investigated
here. Only a single similar comparison study has been
reported.10
2. Methods2.1. PatientsThe enrollment criterion was histologically proven non-
Hodgkin’s lymphoma that was considered to originate from
the gastrointestinal tract, either with main lesions or at least
with adequate gastrointestinal specimens for pathological
review. The earlier biopsies were classified according to the
now obsolete Working Formulation and the Revised Euro-
peaneAmerican Lymphoma classification. Later, World
Health Organization classification system was used. Patients
with MALT lymphomas and those without adequate clinical
information in our hospital were excluded. Among 972 newly
diagnosed lymphoma patients in our hospital, 84 patients withTable 1
Clinical characteristics of patients with gastric and intestinal lymphomas
Parameters (median; range) Classification
Gast
Gender Male 36 (
Female 23 (
Age (69 years; 20e87 years) &60 years 14 (
>60 years 45 (
Histology B-cell 57 (
T-cell 2 (
Low-grade component 5 (
Musshoff staging I 11 (
II 11 (
III 10 (
IV 27 (
B symptoms 10 (
Bulky lesions S10 cm 3 (
Performance status 0, 1 35 (
2e4 24 (
IPI Low 13 (
Low-intermediate 17 (
High-intermediate 11 (
High 18 (
Hemoglobin (11.1 g/dL; 6.1e15.2 g/dL) S12 g/dL 22 (
<12 g/dL 37 (
LDH (267 U/L; 129e3540 U/L) &205 U/L 16 (
>205 U/L 35 (
Albumin (3.2 g/dL; 1.8e4.5 g/dL) S3.7 g/dL 10 (
<3.7 g/dL 42 (
IPI¼ International Prognostic Index; LDH¼ lactate dehydrogenase; NS¼ not signnonMALT lymphomas of gastrointestinal origin between
January 2001 and February 2010 were included in our study.
Staging procedures included physical examination,
complete blood cell count with differential count, blood
chemistry, and computed tomography of the chest, abdomen
and pelvis. Bone marrow aspiration and biopsy were essential
for staging but some patients who received only surgery or
palliative treatment did not undergo bone marrow examina-
tion. Endoscopic examinations and positron emission tomog-
raphy were optional choices. The clinical evaluations included
the performance status based on the Eastern Cooperative
Oncology Group scale, B symptoms (tumor fever, night
sweating and loss of more than 10% of body weight), the
International Prognostic Index (IPI) and bulky lesions (mass of
10 cm or more in the longest diameter).
Clinical stage was defined according to the Musshoff
modification of the Ann Arbor system. Stage I disease was
defined as single gastrointestinal lesion. Stage II was defined as
disease extending into either local or distant abdominal lymph
nodes. Stage III denoted nodal involvement above and below
the diaphragm. Stage IV denoted noncontinuous visceral
organs or bone marrow involvement. For response evaluation,
disappearance of all lesions for a period of 4 weeks with
negative endoscopic finding (if done) was defined as complete
remission (CR). At least 50% decrease in mass was defined as
partial remission (PR). New lesions or increased size of lesions
were classified as progressive disease (PD). Patients who were
not classified as CR, PR or PD were classified as stable disease.No. of patients (%) p
ric lymphoma (n¼ 59) Intestinal lymphoma (n¼ 25)
61) 15 (60) NS
39) 10 (40)
23.7) 15 (60) 0.002
76.3) 10 (40)
96.6) 18 (72) 0.002
3.4) 7 (28)
8.5) 2 (8) NS
18.6) 6 (24) NS
18.6) 5 (20)
16.9) 3 (12)
45.8) 11 (44)
16.9) 8 (32) NS
5.2) 4 (16) NS
59.3) 21 (84) 0.042
40.7) 4 (16)
22.0) 10 (40) NS
28.8) 9 (36)
18.6) 4 (16)
30.5) 2 (8)
37.3) 11 (44) NS
62.7) 14 (56)
31.4) 9 (56.3) NS
68.6) 7 (43.8)
19.2) 8 (38.1) NS
80.8) 13 (61.9)
ificant.
Table 3
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The histological subtypes of gastric and intestinal lymphomas
Classifications No. of patients (%) p
Gastric
lymphoma
(n¼ 59)
Intestinal
lymphoma
(n¼ 25)
Diffuse large B-cell lymphoma 49 (83.1) 13 (52) 0.006
Peripheral T-cell lymphoma 2 (3.4) 4 (16) NS
Mantle cell lymphoma 1 (1.7) 2 (8.0) NS
Enteropathy associated
T-cell lymphoma
0 (0) 3 (12) 0.024
Follicular lymphoma 1 (1.7) 1 (4.0) NS
B-cell lymphoma, unclassified 4 (6.8) 0 (0) NS
Diffuse large lymphoma 1 (1.7) 1 (4.0) NS
Diffuse mixed small and large
cell lymphoma
0 (0) 1 (4.0) NS
High-grade B-cell lymphoma 1 (1.7) 0 (0.0) NS
NS¼ not significant.The categorical variables were compared using Fisher’s
exact test and Chi-square test as appropriate. Overall survival
(OS) was recorded from the date of diagnosis to the date of
death or last follow-up alive. Progression-free survival (PFS)
was the time from the start of curative treatment to the time of
disease progression or persisting CR until last follow-up. The
KaplaneMeier method was used to calculate OS and PFS, and
the comparison between groups was performed through the
logrank test. The univariate and multivariate analyses of
prognostic factors were estimated using Cox’s proportional
hazards model. A p< 0.05 was taken to be two-tailed statisti-
cally significant. Statistical analyses were performed using
SPSS software Version 12.0 for Windows (SPSS Inc., Chicago,
IL, USA).
3. Results3.1. Patient characteristicsThe entire population was divided into groups of gastric
lymphomas (n¼ 59) and intestinal lymphomas (n¼ 25). Two
patients revealed noncontinuous gastric and duodenal
involvement. Another four patients had separate lesions of the
intestine. They were classified as gastric and intestinal
lymphoma, respectively. One patient had acquired immuno-
deficiency syndrome, and two patients had autoimmune
diseases. Intestinal lymphoma patients were significantly
younger and had better performance ( p¼ 0.002 and 0.042).
The other characteristics disclosed no significant difference
between these two groups (Table 1).
The common manifestations of enrolled patients included
abdominal pain (61.9%), nonspecific complaints (45.2%),
bleeding (33.3%), body weight loss (27.4%) and anemia
(22.6%). However, gastrointestinal obstruction and intussus-
ception were significantly more common in the intestinalTable 2
The initial presentations of gastric and intestinal lymphoma patients
Manifestations No. of patients (%) p
Gastric
lymphoma
(n¼ 59)
Intestinal
lymphoma
(n¼ 25)
Abdominal pain 35 (59.3) 17 (68) NS
Nonspecific complaints 25 (42.4) 13 (52) NS
Bleeding 24 (40.7) 4 (16) 0.042
Body weight loss 15 (25.4) 8 (32) NS
Anemia 13 (22) 6 (24) NS
Perforation 4 (6.8) 2 (8) NS
Dysphagia 4 (6.8) 1 (4) NS
Fever 4 (6.8) 0 (0) NS
Constipation 3 (5.1) 1 (4) NS
Mass 1 (1.7) 2 (8) NS
Intestinal obstruction 0 (0) 3 (12) 0.024
Intussusception 0 (0) 3 (12) 0.024
Sweating 1 (1.7) 1 (4) NS
Diarrhea 1 (1.7) 1 (4) NS
NS¼ not significant.group than in the gastric counterpart ( p¼ 0.024 and 0.024).
By contrast, manifestation of various degrees of bleeding was
significantly more frequent in gastric lymphomas than in the
intestinal counterpart ( p¼ 0.042) (Table 2). Histologically,
73.8% of all patients were classified as DLBCL, which was
more common in the gastric group ( p¼ 0.006). Of the total
patients, 10.7% had T-cell type lymphoma, and all enteropathy
associated T-cell lymphomas originated from the intestine
( p¼ 0.024). However, the other histological subtypes
demonstrated equal distribution in these subgroups (Table 3).
In total, 8.3% (n¼ 7) of patients showed evidence of trans-
formation from low-grade MALT lymphoma.
Of all the patients, 28.6% received chemotherapy only,
26.2% had an operation followed by chemotherapy, 19%
underwent single surgery, and 16.7% received palliative
treatment for old age, poor performance or refusal of aggres-
sive treatment. In total, 34.5% underwent multimodality
treatment. Between the subgroups, no statistical significance
was displayed in these managements (Table 4). In the analysis
of individualized modality, 50% of all patients received
surgery, and the percentage was significantly higher in the
intestinal group ( p¼ 0.002) (Table 5). Among intestinalTable 4
Treatment modalities and overall response of included patients
Treatment modalities No. of patients (%)
Gastric
lymphoma
(n¼ 59)
Intestinal
lymphoma
(n¼ 25)
Response
rate
Chemotherapy alone 19 (32.2) 5 (20) 14/15 (93.3)
Surgery & chemotherapy 13 (22) 9 (36) 16/19 (84.2)
Surgery 8 (13.6) 8 (32) 5/8 (62.5)
Surgery &
chemotherapy & radiotherapy
1 (1.7) 1 (4.0) 2/2 (100)
Chemotherapy & salvage surgery 2 (3.4) 0 (0) 2/2 (100)
Chemotherapy & transplantation 1 (1.7) 1 (4.0) 2/2 (100)
Chemotherapy & radiotherapy 1 (1.7) 0 (0) 1/1 (100)
Radiation 1 (1.7) 0 (0) 1/1 (100)
Supportive care 13 (22) 1 (4) d
All p values were not significant ( p> 0.05).
Table 5
Individualized interventions performed in gastric and intestinal lymphomas
Treatment modalities No. of patients (%) p
Gastric
lymphoma (n¼ 59)
Intestinal
lymphoma (n¼ 25)
Surgery 24 (40.7) 18 (72) 0.002
Chemotherapy 37 (62.7) 16 (64) NS
Radiotherapy 3 (5.4) 1 (4) NS
Rituximab 18 (30.5) 6 (24) NS
Transplantation 1 (1.7) 1 (4) NS
NS¼ not significant.
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manifested with obstruction, 16.7% (n¼ 3) with intussuscep-
tion, 16.7% (n¼ 3) with perforation, 16.7% (n¼ 3) with
bleeding and 11.1% (n¼ 2) with masses for exploratory
laparotomy. Actually, only 22.1% (n¼ 4) received intended
curative surgery.3.2. OutcomeThe median duration of follow-up was 10.2 months
(0.1e104.9 months). During the observation period, 41
patients (48.8%) died and 24 patients (28.6%) suffered from
disease progress or relapse. The most common causes of death
were infection (58.5%), disease progress (24.3%) and bleeding
(14.6%). The CR and PR rate in all patients receivingFig. 1. Whole population treatment outcomes demonstrated by KaplaneMeier
significantly prolonged the overall survival ( p¼ 0.0002 and 0.0018) but surgery did
had no significant impact on progression-free survival ( p¼ 0.6116 and 0.2892 respe
survival in comparison with those without rituximab ( p¼ 0.0254).interventions and restaging were 66.7% (34 out of 51) and
17.6% (9 out of 51), respectively. In the subgroup analysis,
gastric and intestinal lymphoma were 68.6% (24 out of 35)
and 62.5% (10 out of 16) for the CR rate, and 22.9% (8 out of
35) and 6.3% (1 out of 16) for the PR rate ( p¼ 0.1060). The
rates of 1-year and 2-year OS were 57.7% and 47.1% in the
gastric group, and 64.7% and 48.5% in the intestinal coun-
terpart ( p¼ 0.7758). The percentages of 1-year and 2-year
PFS were 74.2% and 70.6% in gastric lymphomas and
51.3% and 30.8% in intestinal lymphomas ( p¼ 0.1248). The
overall response rates were similar under different combina-
tions of treatment modalities (Table 3). In the KaplaneMeier
analysis of the whole population, the administration of
chemotherapy and rituximab significantly prolonged the OS
( p¼ 0.0002 and 0.0018) but surgery did not ( p¼ 0.1704).
Instead of chemotherapy and surgery ( p¼ 0.6116 and
0.2892), the introduction of rituximab significantly extended
the PFS ( p¼ 0.0254; Fig. 1). The complications of all treat-
ments included neutropenic fever (28.6%), hemorrhage
(3.6%), perforation (3.6%), obstruction (2.4%), congestive
heart failure (1.2%) and chronic hepatitis B with reactivation
(1.2%) but no significant difference was noted between the
gastric and intestinal groups.
In the univariate analysis of OS for gastric lymphomas,
poor performance status, high IPI, low albumin, no chemo-
therapy and no rituximab were poor prognostic factors.
However, chemotherapy administration (hazard ratio [HR]:survival curves. (AeC) The administration of chemotherapy and rituximab
not ( p¼ 0.1704). (DeF) The undergoing or not of chemotherapy and surgery
ctively). However, patients receiving rituximab had a superior progression-free
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and high IPI (HR: 1.7; 95% CI: 1.181e2.448; p¼ 0.004)
proved to have independently prognostic significance in
multivariate analysis of OS in gastric lymphomas. In the
multivariate analysis of intestinal lymphomas, T-cell lineage
(HR: 8.615; 95% CI: 2.165e34.288; p¼ 0.002) and poor
performance (HR: 9.374; 95% CI: 1.497e58.712; p¼ 0.017)
were demonstrated to be significantly poor predictors of OS.
In the univariate analysis of OS in the pooling of all patients,
T-cell histology, poor performance status, high IPI, low
albumin, no chemotherapy and no rituximab were poor
prognostic factors. Furthermore, poor performance status (HR:
4.276; 95% CI: 2.062e8.867; p< 0.001) and low albumin
(HR: 4.725; 95% CI: 1.072e20.830; p¼ 0.04) confirmed the
statistical significance in the multivariate analysis of OS
(Table 6). Rather, no single factor showed predictive values of
PFS in the gastric group, the intestinal group, and even in all
patients.
4. Discussion
The principles of lymphoma management are based on
histological classifications. Because of the unique pathogen-
esis, H pylori eradication is the standard frontline treatment of
most gastric MALT lymphomas. According to the recom-
mendation of the National Comprehensive Cancer Network,
treatments of gastric MALT lymphomas should be individu-
alized in clinical practice and have been isolated from the other
non-Hodgkin’s lymphomas. At the same time, interventions at
diagnosis of gastrointestinal lymphomas are usually proposed
to prevent possible lethal complications (gastrointestinal
obstruction, bleeding and perforation), even in indolent
diseases other than gastric MALT lymphomas.11,12 Therefore,
the separation of MALT lymphomas from other gastrointestinal
lymphomas was reasonable, and the comparison between
gastric and intestinal nonMALT lymphomas was informative.
Histological classification also determines a major part of
the clinical course and treatment response in gastrointestinal
lymphomas. Chemotherapy shows high activity in B-cell
lymphomas, and the role of surgery is limited. By contrast, T-
cell intestinal lymphoma usually presents with severe surgical
complications, advanced stage, aggressive course and poor
response to treatment.13,14 In our study, DLBCL was the most
common histological subtype in either gastric or intestinal
lymphomas but the percentage was significantly higher in the
gastric group (83.1% vs. 52.0%; p¼ 0.006). However, T-cell
lymphoma was significantly more common in intestinal than
in gastric lymphomas (28.0% vs. 3.4%; p¼ 0.002). T-cell
lineage adversely affected the OS and PFS in the intestinal
group ( p¼ 0.0011 and 0.0405) but the impact was not as
demonstrated in the gastric counterpart (Fig. 2) because of
inadequate numbers of T-cell gastric lymphoma patients
(n¼ 2; p¼ 0.9662 and 0.3358).
In gastric lymphomas, the role of first-line immunoche-
motherapy has been well established, and surgical intervention
has shifted to become the salvage treatment of unsatisfactory
conservative treatments or complications.15e17 Owing to
Fig. 2. Survival, outcomes analyzed between histological subgroups. (A, B) Because of limited numbers of T-cell lymphomas, similar overall survival and
progression-free survival rates were demonstrated between B- and T-cell gastric lymphomas ( p¼ 0.9662 and 0.3358 respectively). (C, D) By contrast, intestinal
lymphomas with T-cell lineage had significantly inferior overall survival and progression-free survival rates compared to those with B-cell lineage ( p¼ 0.0011 and
0.0405, respectively).
405L.-P. Chen et al. / Journal of the Chinese Medical Association 74 (2011) 400e407tumor histology and the study covering a period of 10 years,
33.9% (n¼ 20) received chemotherapy with cyclophospha-
mide, anthracycline, vincristine and prednisolone (CHOP) and
25.6% (n¼ 15) of patients received rituximab plus CHOP
as first-line chemotherapy. Chemotherapy, rather than surgery
and rituximab, was proven to have protective significance
for OS in gastric lymphoma. Also, there was no significant
increase in complications for those patients receiving
chemotherapy with CHOP, even after adding rituximab.18
Nevertheless, the importance of rituximab might be under-
estimated because the sample size was limited.
In some studies of intestinal lymphomas, surgical resection
has proven to be beneficial for local control but controversies
still exist concerning chemotherapy.9,19,20 In another study,
the combination of surgery and chemotherapy showed good
management of complications and obtained a high remission
rate in localized intestinal lymphomas.21 In this study, the
manifestations of surgical emergencies of intestinal obstruction
and intussusception were significantly more common
( p¼ 0.024 and 0.024), and therefore more patients receivedsurgical resection ( p¼ 0.002). In addition, intestinal perfora-
tion, bleeding andmasses for exploratory laparotomywere also
important indications for operations. In total, 55.6% (n¼ 14)
of intestinal lymphoma patients receiving surgery were also
prescribed chemotherapy. However, neither surgery nor
chemotherapy proved beneficial in the OS or PFS of intestinal
lymphomas. Rather, it was proved that histological subtypes
and performance status were the significant prognostic indi-
cators in the multivariate analysis of OS. From the results, it
was inconclusive whether the therapeutic efficacy came from
chemotherapy, operation or both. In short, there is still a role for
surgery in intestinal lymphomas because the manifestations of
surgical emergencies are more common than in gastric
lymphomas. The current trend of treatment tends to combine
surgical resection and chemotherapy in localized intestinal
lymphoma but it is still not well documented.
In this study, the locations of gastrointestinal lymphomas, in
order of frequency, were the stomach (70.2%), small intestine
(13.2%), ileocecal region (10.6%), colon (3.6%), appendix,
(1.2%) and rectum (1.2%). Neither overall response, PFS nor
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intestinal groups ( p¼ 0.106, 0.7758 and 0.1248, respectively).
The site of lymphoma origin was prognostic in a previous
report but the superiority of outcome was not echoed in our
study even though the tumor distribution was similar.22 The
major explanation for this finding might be the exclusion of
MALT lymphoma patients from the study and therefore the
survival rate of patients with gastric lymphomas decreased.
The minor explanation is likely to be the bias of younger and
better performance status in the intestinal group. In the litera-
ture review, four lymphoma subgroups were analyzed in
a German study: the stomach, ileococeal region, small bowel
and multiple sites of origin. Superior survival outcomes were
confirmed in the gastric and ileocecal subgroups.22 If the
gastric and ileocecal lymphoma subgroups had better outcomes
than others, the inclusion of ileocecal lymphoma patients into
the intestinal group should lengthen the survival of the intes-
tinal group and thus make its survival comparable with that of
patients with gastric lymphoma in the present study. In addi-
tion, the fact that tumor location had no significant impact on
outcomes was shown in the study of gastrointestinal DLBCL.20
This indirect evidence further supported our result because
DLBCL was the predominate subtype in both groups.
However, there are some limitations to this study. Firstly, it
was a small-scale retrospective analysis with some missing
data. Secondly, different histological classification systems
were used at different time points and hence the true incidence
of DLBCL may be underestimated. Thirdly, we could not
validate the role of surgery in intestinal lymphoma directly
through lack of head-to-head comparison. Fourthly, no signif-
icant prognostic factor of PFS was found; the assumed prob-
able reason was inadequately analyzed parameters. Some other
factors, such as pathological characteristics,23,24 cytogenetic
abnormalities,25 beta-2 microglobulin26 and absolute lympho-
cyte count27 might also have had an impact on the outcomes.
Finally, the number of patients receiving IFRT and autologous
stem cell transplantation was extremely low.
In conclusion, intestinal lymphomas differ from gastric
lymphomas in manifestation, histology, management and
prognosis. Surgery still plays a role in intestinal lymphomas
because the initial presentations of surgical emergencies are
more common, especially those of intestinal obstruction and
intussusception. In addition, the outcome of gastric lymphomas
compared with intestinal lymphomas is no longer superior if
patients with MALT lymphomas are excluded. Because of the
limited number of enrolled patients, further large-scale studies
are warranted to validate these results.References
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